November 1, 2017 08:15 AM EDTUpdated May 26, 08:50 PM

#ASH17: Bluebird touts early signs that its new-and-improved sickle cell gene therapy is working

John Carroll

Editor & Founder

Bluebird bio $BLUE says they’ve been able to gather evidence to help prove that their new-and-improved approach to making a gene therapy for sickle cell …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

#ASH17: Bluebird touts early signs that its new-and-improved sickle cell gene therapy is working

John Carroll

Editor & Founder

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

BridgeBio shares promising results in trial of Canavan disease gene therapy

CRISPR therapy reduces swelling attacks by 81% in Intellia follow-up study

Facing lost rebates, MGM Resorts to stop covering GLP-1 weight loss shots

Exclusive: University of Toronto spinout raises $53.5M to create new obesity drugs with AI

Icon's quarterly earnings hit by biotech and pharma pullback

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

#ASH17: Blue­bird touts ear­ly signs that its new-and-im­proved sick­le cell gene ther­a­py is work­ing

Editor & Founder

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

#ASH17: Bluebird touts early signs that its new-and-improved sickle cell gene therapy is working